Literature DB >> 10920611

The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh.

R P Croft1, P G Nicholls, J H Richardus, W C Smith.   

Abstract

In this paper, the outcome of 132 patients having acute nerve function impairment (NFI) is reported at 4 and 12 months after the start of prednisolone treatment. In all, 68% of sensory nerves and 67% of motor nerves showed improvement at 12 months, with no statistical difference in responsiveness of various nerves to prednisolone. Duration and severity of impairment were not found significant predictors of treatment outcome. A core of 32% of impaired nerves did not respond to prednisolone, and 12% of impaired nerves had functional deterioration despite treatment. The mean eye-hand-foot (EHF) score improved from 2.02 to 1.33 in the treatment group (median score improved from 2 to 1). Approximately one-third of all patients requiring prednisolone treatment did not receive it, an important reason being that some patients developed new NFI against a background of chronic impairment, and were thus overlooked. The 'unjustly untreated' group of patients had a spontaneous sensory nerve function improvement rate of 62% and a motor nerve function improvement rate of 33% at 12 months from onset of NFI. The EHF score showed no statistically significant improvement.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10920611     DOI: 10.5935/0305-7518.20000018

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  8 in total

Review 1.  Leprosy elimination-a virtual phenomenon or a reality?

Authors:  Diana N J Lockwood
Journal:  BMJ       Date:  2002-06-22

2.  Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions.

Authors:  Anna K Andersson; MeherVani Chaduvula; Sara E Atkinson; Saroj Khanolkar-Young; Suman Jain; Lavanya Suneetha; Sujai Suneetha; Diana N J Lockwood
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

3.  Peripheral Neuropathy Due to Leprosy.

Authors:  Sharon P. Nations; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.972

4.  Progression of leprosy disability after discharge: is multidrug therapy enough?

Authors:  Anna Maria Sales; Dayse Pereira Campos; Mariana Andrea Hacker; José Augusto da Costa Nery; Nádia Cristina Düppre; Emanuel Rangel; Euzenir Nunes Sarno; Maria Lucia Fernandes Penna
Journal:  Trop Med Int Health       Date:  2013-09       Impact factor: 2.622

5.  Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B.

Authors:  Renuka Raju; Sujai Suneetha; Rupendra S Jadhav; MeherVani Chaduvula; Sara Atkinson; Suman Jain; Leo H Visser; Loretta Das; Ravindra Panhalkar; Vidyagouri Shinde; Parphananda P Reddy; Pramila Barkataki; Diana Nj Lockwood; Wim H Van Brakel; Lavanya M Suneetha
Journal:  Lipids Health Dis       Date:  2014-07-28       Impact factor: 3.876

6.  A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.

Authors:  Saba M Lambert; Digafe T Alembo; Shimelis D Nigusse; Lawrence K Yamuah; Stephen L Walker; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2016-04-05

7.  Grade 2 disabilities in leprosy patients from Brazil: Need for follow-up after completion of multidrug therapy.

Authors:  Marcos Túlio Raposo; Martha Cerqueira Reis; Ana Virgínia de Queiroz Caminha; Jörg Heukelbach; Lucy Anne Parker; Maria Pastor-Valero; Maria Ines Battistella Nemes
Journal:  PLoS Negl Trop Dis       Date:  2018-07-16

8.  Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial.

Authors:  Inge Wagenaar; Erik Post; Wim Brandsma; Bob Bowers; Khorshed Alam; Vanaja Shetty; Vivek Pai; Sajid Husain; Cita Rosita Sigit Prakoeswa; Linda Astari; Deanna Hagge; Mahesh Shah; Kapil Neupane; Krishna Bahadur Tamang; Peter Nicholls; Jan Hendrik Richardus
Journal:  PLoS Negl Trop Dis       Date:  2017-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.